Daniel Hunter

Daniel joined Exponent in January 2020, having previously worked at Allen & Overy and Goldman Sachs.

Since then, he has been involved in the Xeinadin transaction.

Born and raised in Cheshire, he has an MA in Law from Oxford University and an MBA from INSEAD.